Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 3:44 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 36 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: topical Timolol Clear all

Conditions: Sturge Weber Syndrome, Port-wine Mark
Interventions: Timolol, Preservative free artificial tear gel.; Drug
Lead sponsor: Wills Eye; Other
Eligibility: 2 Years to 10 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Ocular Hypertension, Open Angle Glaucoma
Interventions: BOL-303259-X, Timolol maleate; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 40 Years to 90 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Macular Hole, Retinal Detachment
Interventions: Dorzolamide 2%-timolol 0.5% topical eyedrops; Drug
Lead sponsor: Mid Atlantic Retina; Other
Eligibility: Not listed
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Surgical Wounds, Mohs Surgery
Interventions: Topical Timolol, Normal Saline; Drug
Lead sponsor: Geisinger Clinic; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Danville, Pennsylvania

Conditions: Wet Macular Degeneration, Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
Interventions: Dorzolamide-timolol; Drug
Lead sponsor: Wills Eye; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Ulcer, Burns
Interventions: Timoptic, Placebo; Drug · Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Mather, California

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: Travoprost Ophthalmic Topical Cream low-dose, Travoprost Ophthalmic Topical Cream mid-dose, Travoprost Ophthalmic Topical Cream high-dose, Timolol maleate ophthalmic solution, 0.5%, Travoprost Ophthalmic Solution, 0.004%; Drug
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Hemangioma
Interventions: topical timolol maleate, Pulsed dye laser; Drug · Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: Up to 3 Months
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Glaucoma
Interventions: Prostaglandin Analogue -Containing IOP-Lowering Therapy, Beta Blocker, Brillouin Microscopy; Drug · Device
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: BOL-303259-X, Timolol; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Scleral Buckling
Interventions: Timolol-dorzolamide (Glaucoma drops), standard post-operative topical drops; Drug
Lead sponsor: Jason Hsu, MD; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: DE-112, DE-112 Vehicle Solution, Timolol Maleate Solution; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Austin, Texas • San Antonio, Texas

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: BOL-303259-X, Timolol; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Hemangioma, Infant
Interventions: topical 0.5% Timolol, Control (placebo) group; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 1 Month to 8 Months
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Infantile Hemangiomas
Interventions: Timolol 0.5% Gel Forming Solution (GFS), Mupirocin 2% Ointment; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 1 Month to 8 Months
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Glaucoma and Ocular Hypertension
Interventions: DE-117 Ophthalmic Solution, Timolol Maleate Ophthalmic Solution 0.5%; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 12 Months and older
Enrollment: 417 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 34
States / cities: Chandler, Arizona • Prescott, Arizona • Glendale, California + 29 more

Conditions: Infantile Hemangioma, Very Low Birth Weight Infants
Interventions: topical 0.5% Timolol maleate, Control (placebo) group; Drug
Lead sponsor: Alice K. Gong; Other
Eligibility: Up to 6 Months
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Infantile Hemangioma
Interventions: Propranolol three times a day, Propranolol twice a day, Timolol; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: Up to 18 Months
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Infantile Hemangiomas
Interventions: Not listed
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 1 Month to 5 Years
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Glaucoma; Drugs
Interventions: CATS Tonometer, Latanoprost; Device · Drug
Lead sponsor: Intuor Technologies, Inc.; Industry
Eligibility: 18 Years to 101 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Chronic Diabetic Foot Ulcers, Diabetic Neuropathic Ulcers, Non Healing Wound
Interventions: Timolol, Non biologically active gel; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Infantile Hemangioma
Interventions: 0.25% Timolol Maleate Gel Forming Solution, 0.5% Timolol Maleate Gel Forming Solution; Drug
Lead sponsor: Kanecia Obie Zimmerman; Other
Eligibility: Up to 84 Days
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 12
States / cities: Chicago, Illinois • Indianapolis, Indiana • Baltimore, Maryland + 9 more

Conditions: Wound Healing, Mohs Micrographic Surgery
Interventions: Timolol Maleate Solution, Standard of Care; Drug · Other
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Hemangioma
Interventions: timolol maleate 0.5% gel; Drug
Lead sponsor: Rady Children's Hospital, San Diego; Other
Eligibility: 7 Days to 6 Months
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: San Diego, California

Search by objective public record fields.

Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol

BOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Effect of Topical Aqueous Suppressants on Intraocular Gas Duration Following Pars Plana Vitrectomy

The Effects of Timolol On Healing and Cosmesis of Mohs Scalp Wounds: An Open Label Trial

Dorzolamide-timolol Drops With Injections to Treat AMD, RVO or DME.

Beta Blocker for Chronic Wound Healing

Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension

A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn

Study of Corneal Biomechanics in Glaucoma Patients Using Brillouin Microscopy

Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension

The Effect of Glaucoma Drops on of the Duration of a Pure Intraocular Gas Bubble

Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular Hypertension

Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Topical Timolol 0.5% Solution for Proliferating Infantile Hemangiomas

Timolol Option for Ulcerated Hemangiomas (TOUCH Trial)

A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study

Timolol for the Prevention of Proliferation of Infantile Hemangioma (TiPPIH Trial)

Assessing the Impact of Dosage Frequency of Propranolol on Sleep Patterns in Patients With Infantile Hemangiomas

Ontogeny of Infantile Hemangiomas With Skin Imaging Modalities

CATS Tonometer IOP Reduction Latanoprost Verses Timolol

Beta Adrenergic Antagonist for the Healing of Chronic DFU

Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH)

Topical 0.5% Timolol Solution for Healing Lower Extremity Wounds

Topical Timolol Gel for the Treatment of Infantile Hemangiomas